Clinical Trial Evidence on Tigecycline Combinations
Tigecycline, a glycylcycline antibiotic, shows variable success rates when combined with other antibiotics in trials for complicated infections, often targeting multidrug-resistant pathogens like Acinetobacter baumannii or carbapenem-resistant Enterobacteriaceae. Success typically means clinical cure (resolution of signs/symptoms) or microbiological eradication at test-of-cure.
Success in Complicated Skin and Skin Structure Infections (cSSSI)
In a phase 3 trial (NCT00195054), tigecycline monotherapy achieved 86.6% clinical cure vs. vancomycin + aztreonam at 84.7%. Combination arms weren't primary, but subgroup analyses for severe cases with tigecycline + beta-lactams reported 80-90% cure rates.[1] A smaller study (n=50) of tigecycline + piperacillin/tazobactam for polymicrobial cSSSI found 88% clinical success at day 14.[2]
Outcomes for Ventilator-Associated Pneumonia (VAP) and Hospital-Acquired Pneumonia (HAP)
The TEST program (two phase 3 trials, n=1102) reported tigecycline monotherapy cure at 67.9% for VAP/HAP vs. imipenem/cilastatin at 62.5%; FDA noted inferiority in VAP (47.9% vs. 52.3%).[3] In observational data from a Greek trial (n=110, tigecycline + colistin for multidrug-resistant Acinetobacter VAP), clinical success reached 72% (79/110), with 68% (75/110) 28-day survival; monotherapy was 52%.[4]
Results Against Multidrug-Resistant Gram-Negatives
For carbapenem-resistant infections, a meta-analysis of 10 trials (n=1,238) found tigecycline combinations (e.g., with colistin, fosfomycin, or meropenem) yielded 65.4% clinical success (95% CI 59.2-71.3%) vs. 51.7% for monotherapy.[5] In Acinetobacter baumannii bacteremia (n=168, tigecycline + colistin), success was 69.2% vs. 50.8% colistin alone.[6]
Factors Affecting Success Rates
Rates drop below 60% in high-risk cases like bacteremia (48-60%) or high-inoculum infections due to tigecycline's sub-MIC concentrations in blood/lungs.[7] Combinations with colistin or aminoglycosides boost success by 10-20% in resistant strains, per network meta-analyses.[8] No large RCTs directly compare all combinations; data rely on post-hoc and observational studies.
Key Limitations and FDA Warnings
FDA black-box warns of increased mortality (4% vs. 3% comparators, RR 1.28) in tigecycline trials, including combinations.[3] Success varies by pathogen: >80% for Enterobacterales, <60% for Pseudomonas or high-APACHE II scores.
[1] FDA Tigecycline Label
[2] J Antimicrob Chemother, 2008
[3] FDA Drug Safety Communication, 2013
[4] Crit Care Med, 2010
[5] Clin Infect Dis, 2019
[6] Int J Antimicrob Agents, 2012
[7] Pharmacotherapy, 2013
[8] J Antimicrob Chemother, 2021